Sfoglia per AUTORE
ROBOTTI M
Collezione ASL Asti

  

Items : 6

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study. in Neurology and therapy / Neurol Ther. 2024 Oct;13(5):1505-1506. doi: 10.1007/s40120-024-00648-z.

2024
ASL Asti

Barbanti P; Egeo G; Proietti S; d'Onofrio F; Aurilia C; Finocchi C; Di Clemente L; Zucco M; Doretti A; Messina S; Autunno M; Ranieri A; Carnevale A; Colombo B; Filippi M; Tasillo M; Rinalduzzi S; Querzani P; Sette G; Forino L; Zoroddu F; Robotti M; Valenza A; Camarda C; Borrello L; Aguggia M; Viticchi G; Tomino C; Fiorentini G; et alii...

Correction to: Ultra-late response (>?24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. in Journal of neurology / J Neurol. 2024 May;271(5):2444-2445. doi: 10.1007/s00415-024-12287-3.

2024
ASL Asti

Carnevale A; Robotti M; Salerno A; Grazzi L; Favoni V; di Poggio MLB; Colombo B; Cetta I; Di Clemente L; Zucco M; Orlando B; Fiorentini G; Cevoli S; Finocchi C; Trimboli M; Bertuzzo D; Aguggia M; Torelli P; D'Onofrio F; Proietti S; Egeo G; Aurilia C; Barbanti P; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;

Ultra-late response (>?24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. in Journal of neurology / J Neurol. 2024 May;271(5):2434-2443. doi: 10.1007/s00415-023-12103-4. Epub 2024 Jan 17.

2024
ASL Asti

Carnevale A; Robotti M; Salerno A; Grazzi L; Favoni V; di Poggio MLB; Colombo B; Cetta I; Di Clemente L; Zucco M; Orlando B; Fiorentini G; Cevoli S; Finocchi C; Trimboli M; Bertuzzo D; Aguggia M; Torelli P; D'Onofrio F; Proietti S; Egeo G; Aurilia C; Barbanti P; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study. in Neurology and therapy / Neurol Ther. 2024 Jun;13(3):611-624. doi: 10.1007/s40120-024-00591-z. Epub 2024 Mar 7.

2024
ASL Asti

Borrello L; Aguggia M; Camarda C; Valenza A; Robotti M; Zoroddu F; Forino L; Sette G; Querzani P; Rinalduzzi S; Tasillo M; Filippi M; Colombo B; Carnevale A; Ranieri A; Autunno M; Messina S; Doretti A; Zucco M; Di Clemente L; Finocchi C; Aurilia C; d'Onofrio F; Proietti S; Egeo G; Barbanti P; Viticchi G; Tomino C; Fiorentini G; et alii...

Correction to: Ultra-late response (>?24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study (Journal of Neurology, (2024), 271, 5, (2434-2443), 10.1007/s00415-023-12103-4) in Journal of Neurology

2024
ASL Asti

Barbanti P; Aurilia C; Egeo G; Proietti S; D’Onofrio F; Torelli P; Aguggia M; Bertuzzo D; Finocchi C; Trimboli M; Cevoli S; Fiorentini G; Orlando B; Zucco M; Di Clemente L; Cetta I; Colombo B; di Poggio MLB; Favoni V; Grazzi L; Salerno A; Carnevale A; Robotti M; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;

Correction to: Ultra-late response (>?24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study (Journal of Neurology, (2024), 271, 5, (2434-2443), 10.1007/s00415-023-12103-4) in Journal of Neurology

2024
ASL Asti

Barbanti P; Aurilia C; Egeo G; Proietti S; D’Onofrio F; Torelli P; Aguggia M; Bertuzzo D; Finocchi C; Trimboli M; Cevoli S; Fiorentini G; Orlando B; Zucco M; Di Clemente L; Cetta I; Colombo B; di Poggio MLB; Favoni V; Grazzi L; Salerno A; Carnevale A; Robotti M; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;